spacer
home > ict > Autumn 2010
PUBLICATIONS

International Clinical Trials

ict
Autumn 2010
   
Text
PDF
bullet
REGULATORY

Complicated and rigorous, the safety management process can often become an ardous but necessary burden for trial coordinators to carry. Miriam Marotti at Prism Ideas shows how pharmacovigilance providers can lighten the load.

 

 
view
download pdf
Risk management has become a task for all levels of business operations since the publication of ICHQ9 Quality Risk Management.Andreas Grund of GCP Service International explains how to reassess approaches to risk, ultimately treating them as an opportunity to add value.  
view
download pdf
bullet
TRIAL MANAGEMENT
Paediatric clinical trials pose ethical, regulatory and practical issues,which have led to low interest from pharma companies. Philippa Smit-Marshall at PharmaNet explains how these hurdles can be overcome in sites around the world.  
view
download pdf
Cyril Clarke at ICON Development Solutions shows how the expensive, largely unsuccessful process of researching a new drug can be offset by a shift in the proof-of-concept stage, which aims to minimise the impact of failed Phase III trials.  
view
download pdf
The drug approval process in the EU is faster and more transparent – something which US firms would do well to take advantage of. Angus G Cameron at Pharmarama Inc discusses the details of sourcing EU-approved drugs for bioequivalence studies.  
view
download pdf
bullet
Regional trials
With its large population and highly developed economy, Japan should be a prime location for clinical trials.However, there are a number of obstacles holding the location back, explains Jeremy Buchman at BBK Worldwide.  
view
download pdf
Dana L Niedzielska and Mikhail Kandalov at PPD introduce Russia’s clinical research sector and the rapid progress that has been made in the country’s various regions over the last 15 years, and discuss how further development can be pursued.  
view
download pdf
In a continuation of the eastern European focus,David Passov at ClinStar delves into the financial benefits of choosing to conduct trials in the region, giving examples of how time, and therefore money, can be saved for both sponsor and CRO.  
view
download pdf
The third in the series, Oleg Mediannikov and Denis Pyak at Tetrial CRO focus on the Russia’s response to clinical trials for generic drugs, and point out the regulatory issues that must be overcome by CROs, while also charting the potential for development in the region.  
view
download pdf
Bindhya Cariappa of ClinTec International turns to India and the Gulf region to look at the high prevalence of diabetes in these locations, and how they offer a valuable opportunity for clinical researchers, in terms of both the variety and naivety of the population.  
view
download pdf
eCLINICAL, DATA MANAGEMENT & STATISTICAL ANALYSIS
Nick Halkitis, Liz Moench and Duncan Shaw at MediciGlobal reveal a host of options for online patient recruitment and point out that, despite rapid development in the digital world, clinical researchers in the real world are still playing catch-up.  
view
download pdf
Hard copy records are still firmly ingrained in today’s clinical trials administration systems, despite the clear advantages of electronic archiving has to offer. Dimitri Stamatiadis at Merck Serono highlights these benefits and assesses how change can come about.  
view
download pdf
Scott Dixon of Phase Forward Inc shows how web-based ePRO can improve the information provided by patient reported outcomes, offering a more accessible user experience as well as providing an element of control that appeals to patients.  
view
download pdf
bullet
THERAPEUTICS
Radiography is currently entrenched as the standard FDA-approved method of clinical assessment for rheumatoid arthritis. However,magnetic resonance imaging can be shown to be superior on many counts, as Harris A Ahmad at BioClinica, Inc illustrates.  
view
download pdf
The market for autoimmune disease therapies in the developed world is undergoing rapid growth and companies’ sales are increasing accordingly. However, James Wentworth at Datamonitor believes less developed economies may also harbour similar untapped potential.  
view
download pdf
bullet
Drug delivery & Therapeutics
Berwyn Clarke and Aino Telaranta-Keerie at Lab21 chart the progress of recent developments in cancer therapeutics; revealing successful avenues for molecular diagnostics in oncology and giving examples of molecules that have not lived up to their potential.  
view
download pdf
Chris Moriarty at Randox Pharma Services explains how a three-pronged offensive can often be the best solution when choosing a diagnostic partner, and provides a breakdown of what factors to consider in the selection process.  
view
download pdf
bullet
Labs & Logistics

Geraint Thomas at Laminar Medica explains how Class 6, Division 6.2 infectious biological substances can present a serious challenge for logistics managers, and offers insight into clinical trial packaging technologies that fulfil the regulation’s requirements.

 
view
download pdf
Editor Graham Hughes looks at The Professional Guinea Pig by Roberto Abadie, which charts the experiences of those who partake in clinical trials for a living.The book examines the patients’ views on the risks they assumed by participating on a regular basis.  
view
download pdf
   
spacer
Edited by
Dr Graham Hughes
Consultant in
Pharmaceutical
Development

Published quarterly in
February, May,
August and November

News and Press Releases

New research confirms correlation of common bacteria (including MRSA) and eczema


More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

Industry Events

PPMA Show 2017

26-28 September 2017, NEC, BIRMINGHAM UK

The PPMA is the UK's trade association for suppliers of processing and packaging machinery to the UK market and represents over 500 member and associate companies. Its principle objective is to promote sales of machinery, both at home and abroad, through various projects and services of mutual benefit to both members and their customers by providing free technical and machinery information and advice.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement